Drug Trial Radar · NCT06834347
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
231
Actual
Start
Feb 12, 2025
Primary completion
Sep 23, 2026
Study completion Mar 26, 2027
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Feb 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
EFC18418 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study with 3 treatment groups. The purpose of the study is to evaluate the efficacy, safety and tolerability of 2 dosing regimens of itepekimab compared to placebo as add-on therapy to intranasal corticosteroids (INCS) in male and female participants with chronic rhinosinusitis with nasal polyps (CRSwNP) aged 18 years of age and older. Study details include: * The study duration per participant (4-week screening, 52-week treatment, 20-week safety follow-up) will be up to 76 weeks. For participants transitioning to the LTS18420 study, the study duration will be 56 weeks. * The treatment duration will be up to 52 weeks. * The number of visits will be 9 site visits and 20 phone/home visits.
Conditions
- Chronic Rhinosinusitis With Nasal Polyps
Interventions
Itepekimab (SAR440340)Drug
Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
PlaceboDrug
Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
Mometasone furoate nasal spray (MFNS)Drug
Pharmaceutical form: Solution for administration via spray pump. Route of administration: Intranasal spray
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the endoscopic NPSTime frame: Baseline to Week 24
- Change from baseline in the NCSTime frame: Baseline to Week 24
Locations
121 sites in 21 countries. Site status is shown where the registry gives one.
University of Southern California (USC) / Keck Medicine of USC- Site Number : 8400037
Arcadia, California
Sensa Health- Site Number : 8400038
Los Angeles, California
Newport Native MD- Site Number : 8400031
Newport Beach, California
Sacramento Ear Nose & Throat - Roseville- Site Number : 8400064
Roseville, California
Breathe Clear Institute of Sinus and Allergy Relief- Site Number : 8400040
Torrance, California
Orso Health - Torrance - Hawthorne Boulevard- Site Number : 8400035
Torrance, California
Advanced Research Associates (ARA) Professionals- Site Number : 8400011
Miami, Florida
Paradisus Med Research - Miami- Site Number : 8400009
Miami, Florida
Orlando ENT Associates - Orlando- Site Number : 8400008
Orlando, Florida
Emory University School of Medicine- Grady Campus- Site Number : 8400047
Atlanta, Georgia
Treasure Valley Medical Research- Site Number : 8400063
Boise, Idaho
University of Chicago Medical Center- Site Number : 8400018
Chicago, Illinois
Deaconess Clinic Allergy East- Site Number : 8400056
Evansville, Indiana
SSM Health Saint Louis University Hospital- Site Number : 8400005
St Louis, Missouri
Northwell Health Physician Partners Rheumatology at Great Neck- Site Number : 8400028
Great Neck, New York
Essential Medical Research- Site Number : 8400066
Tulsa, Oklahoma
TEN20 Clinical Research - Dallas- Site Number : 8400015
Dallas, Texas
Houston Methodist Hospital- Site Number : 8400054
Houston, Texas
ENT Associates of Texas - McKinne- Site Number : 8400062
McKinney, Texas
Alamo ENT Associates- Site Number : 8400065
San Antonio, Texas
Eastern Virginia Medical School (EVMS) Medical Group- Site Number : 8400046
Norfolk, Virginia
Investigational Site Number : 0320001
Buenos Aires, Argentina
Investigational Site Number : 0320005
Buenos Aires, Argentina
Investigational Site Number : 0320003
Mendoza, Argentina
Investigational Site Number : 0320002
La Plata, Buenos Aires, Argentina
Investigational Site Number : 0320004
Rosario, Santa Fe Province, Argentina
Investigational Site Number : 0400005
Graz, Austria
Investigational Site Number : 0400002
Linz, Austria
Investigational Site Number : 0400001
Vienna, Austria
Hospital Israelita Albert Einstein- Site Number : 0760001
São Paulo, Brazil
Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760002
Ribeirão Preto, São Paulo, Brazil
Centro Internacional de Pesquisa Clínica (CIPES)- Site Number : 0760005
São José dos Campos, São Paulo, Brazil
Investigational Site Number : 1240005
London, Ontario, Canada
Investigational Site Number : 1240002
Montreal, Quebec, Canada
Investigational Site Number : 1240001
Québec, Quebec, Canada
Investigational Site Number : 1520006
Valdivia, Los Ríos Region, Chile
Investigational Site Number : 1520003
Talca, Maule Region, Chile
Investigational Site Number : 1520004
Lo Barnechea, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520002
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520001
Santiago, Reg Metropolitana de Santiago, Chile
Showing 40 of 121 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.